DETAILED ACTION
Notice of Pre-AIA or AIA Status
The inventor or joint inventor should note that the instant invention, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Claims
Claims 1-20 are pending in the instant invention. According to the Amendments to the Claims, filed February 26, 2026, claims 1-11, 14-16 and 19 were amended.
Status of Priority
This invention is a 35 U.S.C. § 371 National Stage Filing of International Application No. PCT/EP2021/056585, filed March 16, 2021, which claims priority under 35 U.S.C. § 119(a-d) to EP 20164207.1, filed March 19, 2020.
Status of Restrictions / Election of Species
PNG
media_image1.png
200
400
media_image1.png
Greyscale
The inventor’s or joint inventor’s affirmation of the following election, without traverse, in the reply filed on February 26, 2026, is acknowledged: a) Group I - claims 1-11, 14-16 and 19; and b) substituted carboxamide of formula (I-a) - p. 128, Compound No. 102.
Similarly, the inventor or joint inventor should further note that the requirement was made FINAL in the Non-Final Rejection, mailed on August 27, 2025.
Likewise, the inventor or joint inventor should further note that this invention contains claims 12, 13, 17, 18 and 20, drawn to nonelected inventions, without traverse, in the reply filed on February 26, 2026. A complete reply to the Final Rejection may include cancellation of nonelected claims or other appropriate action (37 CFR 1.144). See MPEP § 821.02.
Next, the inventor or joint inventor should further note that the sections of U.S.C. Title 35 that formed the basis of prior rejections formulated, as well as any references supporting said rejections, that are not included with this Office action, may be found in the Non-Final Rejection, mailed on August 27, 2025.
Moreover, the inventor or joint inventor should further note that any rejections and/or objections of record not explicitly addressed herein below, are hereby withdrawn, in light of the inventor’s or joint inventor’s arguments and/or the Amendments to the Claims, filed February 26, 2026.
Thus, a second Office action and prosecution on the merits of claims 1-11, 14-16 and 19 is contained within.
New Claim Objections
Claim 1 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b), the existing recitation should be replaced with the following recitation:
A compound of formula (I-a), formula (I-b), or formula (I-c):
PNG
media_image2.png
200
400
media_image2.png
Greyscale
(I-a),
PNG
media_image3.png
200
400
media_image3.png
Greyscale
(I-b),
or
PNG
media_image4.png
200
400
media_image4.png
Greyscale
(I-c)
or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof,
wherein:
R1 is ArA or HetarA;
ArA is aryl;
wherein the aryl is monocyclic or bicyclic;
wherein the aryl contains 5, 6, 7, 8, 9, 10, or 11 ring carbon atoms; and
wherein the aryl is optionally substituted with one or more substituents independently selected from the group consisting of RA1, RA2, RA3, RA4, and RA5;
HetarA is heteroaryl;
wherein the heteroaryl is monocyclic or bicyclic;
wherein the heteroaryl contains 5, 6, 7, 8, 9, 10, or 11 ring atoms; and
wherein the heteroaryl contains ring carbon atoms and 1, 2, 3, 4, or 5 ring heteroatoms selected from the group consisting of N, O, and S; and
wherein the heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of RA1, RA2, RA3, RA4, and RA5;
each RA1 is independently D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
each RA2 is independently D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
each RA3 is independently D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
each RA4 is independently D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
each RA5 is independently D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
R2 is ArB or HetarB;
ArB is aryl;
wherein the aryl is monocyclic or bicyclic;
wherein the aryl contains 5, 6, 7, 8, 9, 10, or 11 ring carbon atoms; and
wherein the aryl is optionally substituted with one or more substituents independently selected from the group consisting of RB1, RB2, RB3, RB4, and RB5;
HetarB is heteroaryl;
wherein the heteroaryl is monocyclic or bicyclic;
wherein the heteroaryl contains 5, 6, 7, 8, 9, 10, or 11 ring atoms; and
wherein the heteroaryl contains ring carbon atoms and 1, 2, 3, 4, or 5 ring heteroatoms selected from the group consisting of N, O, and S; and
wherein the heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of RB1, RB2, RB3, RB4, and RB5;
each RB1 is independently D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
each RB2 is independently D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
each RB3 is independently D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
each RB4 is independently D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
each RB5 is independently D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
R3 is C1-6 aliphatic or OC1-6 aliphatic;
R4 is H, D, C1-6 aliphatic, or OC1-6 aliphatic;
R5 is H, D, halogen, C1-6 aliphatic, or OC1-6 aliphatic;
R6 is CH2HetarC or HetarC;
HetarC is heteroaryl;
wherein the heteroaryl is monocyclic or bicyclic;
wherein the heteroaryl contains 5, 6, 7, 8, 9, 10, or 11 ring atoms; and
wherein the heteroaryl contains ring carbon atoms and 1, 2, 3, 4, or 5 ring heteroatoms selected from the group consisting of N, O, and S; and
wherein the heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of RC1, RC2, RC3, RC4, and RC5;
each RC1 is independently D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
each RC2 is independently D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
each RC3 is independently D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
each RC4 is independently D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic; and
each RC5 is independently D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic.
Appropriate correction is required. See MPEP § 2173.02.
Claim 2 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation:
The compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R1 and R2 are the same.
Appropriate correction is required. See MPEP § 2173.02.
Claim 3 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation:
The compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R1 and R2 are different.
Appropriate correction is required. See MPEP § 2173.02.
Claim 4 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation:
The compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:
ArA is trideuterophenyl, tetradeuterophenyl, or pentadeuterophenyl, wherein the trideuterophenyl, tetradeuterophenyl, or pentadeuterophenyl is optionally further substituted with one or two additional substituents independently selected from the group consisting of RA1 and RA2;
HetarA is a monocyclic 5- or 6-membered heteroaryl or a bicyclic 10-membered heteroaryl;
wherein the heteroaryl contains ring carbon atoms and 1 or 2 ring heteroatoms selected from the group consisting of N, O, and S; and
wherein the heteroaryl is optionally substituted with one or two substituents independently selected from the group consisting of RA1 and RA2;
ArB is trideuterophenyl, tetradeuterophenyl, or pentadeuterophenyl, wherein the trideuterophenyl, tetradeuterophenyl, or pentadeuterophenyl is optionally further substituted with one or two additional substituents independently selected from the group consisting of RB1 and RB2; and
HetarB is a monocyclic 5- or 6-membered heteroaryl;
wherein the heteroaryl contains ring carbon atoms and 1 or 2 ring heteroatoms selected from the group consisting of N, O, and S; and
wherein the heteroaryl is optionally substituted with one or two substituents independently selected from the group consisting of RB1 and RB2.
Appropriate correction is required. See MPEP § 2173.02.
Claim 5 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation:
The compound according to claim 4, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:
each RA1 is independently D, F, Cl, C1-4 aliphatic, or OC1-4 aliphatic;
each RA2 is independently D, F, Cl, C1-4 aliphatic, or OC1-4 aliphatic;
each RB1 is independently D, F, Cl, C1-4 aliphatic, or OC1-4 aliphatic; and
each RB2 is independently D, F, Cl, C1-4 aliphatic, or OC1-4 aliphatic.
Appropriate correction is required. See MPEP § 2173.02.
Claim 6 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation:
The compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:
R3 is C1-4 alkyl;
R4 is H; and
R5 is H, F, Cl, C1-4 alkyl, or OC1-4 alkyl.
Appropriate correction is required. See MPEP § 2173.02.
Claim 7 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation:
The compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:
R6 is CH2HetarC or HetarC;
HetarC is a monocyclic 5- or 6-membered heteroaryl;
wherein the heteroaryl contains ring carbon atoms and 1, 2, or 3 ring heteroatoms selected from the group consisting of N, O, and S; and
wherein the heteroaryl is substituted with one or two substituents independently selected from the group consisting of RC1 and RC2;
each RC1 is independently C1-4 alkyl; and
each RC2 is independently C1-4 alkyl.
Appropriate correction is required. See MPEP § 2173.02.
Claim 8 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation:
The compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:
R6 is HetarC;
HetarC is a monocyclic 5-membered heteroaryl;
wherein the heteroaryl contains ring carbon atoms and 2 or 3 ring heteroatoms selected from the group consisting of N and O; and
wherein the heteroaryl is optionally substituted with one RC1 substituent;
RC1 is CH2CH3.
Appropriate correction is required. See MPEP § 2173.02.
Claim 9 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation:
The compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:
ArA is phenyl, monodeuterophenyl, dideuterophenyl, trideuterophenyl, tetradeuterophenyl, pentadeuterophenyl, fluorophenyl, methylphenyl, or methoxyphenyl;
HetarA is methylpyrazolyl, thiophen-2-yl, thiophen-3-yl, methylthiophenyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, or quinolinyl;
ArB is phenyl, monodeuterophenyl, dideuterophenyl, trideuterophenyl, tetradeuterophenyl, pentadeuterophenyl, fluorophenyl, or methylphenyl;
HetarB is thiophen-2-yl, thiophen-3-yl, methylthiophenyl, or pyridinyl;
R3 is CH3 or CH2CH3;
R4 is H;
R5 is H, F, Cl, CH3, CH2CH3, or OCH3;
R6 is HetarC; and
HetarC is ethylpyrazolyl, ethylimidazolyl, ethyloxazolyl, ethyltriazolyl, or ethyloxadiazolyl.
Appropriate correction is required. See MPEP § 2173.02.
Claim 10 is objected to because of the following informalities: a) for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), A compound according to claim 1 selected from the group consisting of:… should be replaced with A compound selected from the group consisting of:…; b) for clarity and precision, any claim may contain tables only if the subject matter of the claim makes the use of tables desirable; however, in the present instance, the use of a table is deemed undesirable (see MPEP § 11.10); and c) for clarity and precision, and should be inserted prior to the last species. Appropriate correction is required. See MPEP § 2173.02.
The examiner suggests for section b), omitting the table and reciting the respective compound numbers and chemical structures, separated by appropriate punctuation (i.e. comma or semicolon) after each chemical structure. See 37 CFR 1.75(i).
Claim 11 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation:
A medicament comprising the compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.
Appropriate correction is required. See MPEP § 2173.02.
Claim 14 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation:
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, as an active ingredient.
Appropriate correction is required. See MPEP § 2173.02.
Claim 15 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation:
The pharmaceutical composition according to claim 14, wherein the pharmaceutical composition further comprises a therapeutically effective amount of a second active ingredient that is not an additional compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.
Appropriate correction is required. See MPEP § 2173.02.
Claim 16 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation:
A kit comprising separate packs of a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, as an active ingredient, and a therapeutically effective amount of a second active ingredient that is not an additional compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.
Appropriate correction is required. See MPEP § 2173.02.
Claim 19 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation:
The compound according to claim 9, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:
ArA is pentadeuterophenyl, 2-fluorophenyl, 2-methylphenyl, or 2-methoxyphenyl;
HetarA is 1-methylpyrazol-3-yl, 1-methylpyrazol-4-yl, 5-methylthiophen-2-yl, 1,3-thiazol-2-yl, pyridin-2-yl, pyridazin-3-yl, pyrimidin-4-yl, or quinolin-2-yl;
ArB is pentadeuterophenyl, 2-fluorophenyl, or 2-methylphenyl;
HetarB is 5-methylthiophen-2-yl or pyridin-2-yl; and
HetarC is 1-ethylpyrazol-3-yl, 1-ethyl-1H-imidazol-4-yl, 4-ethyl-1,3-oxazol-2-yl, 5-ethyl-1,3-oxazol-2-yl, 2-ethyl-2H-1,2,3-triazol-4-yl, 1-ethyl-1H-1,2,4-triazol-3-yl, 5-ethyl-1,2,4-oxadiazol-3-yl, or 5-ethyl-1,3,4-oxadiazol-2-yl.
Appropriate correction is required. See MPEP § 2173.02.
New Claim Rejections - 35 U.S.C. § 112(b)
The following is a quotation of the second paragraph of 35 U.S.C. § 112:
(b) CONCLUSION. The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or joint inventor regards as the invention.
Claims 1-9, 11, 14-16 and 19 are rejected under 35 U.S.C. § 112(b) as being indefinite for failing to set forth the subject matter which the inventor or joint inventor regards as the invention.
The inventor or joint inventor should note that the phrase, optionally substituted, in claim 1, with regard to R3, R4, R5, RA1, RA2, RA3, RA4, RA5, RB1, RB2, RB3, RB4, RB5, RC1, RC2, RC3, RC4, and/or RC5, respectively, is a relative phrase which renders the claim indefinite. The phrase, optionally substituted, is not defined by the claim, the specification does not provide an adequate standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the metes and bounds of the invention. The specification, on page 14, uses open language, such as comprising, to define the term, substituted, with respect to alkyl, as halogen, hydroxy, etc., and further discloses that the substituents themselves may be further substituted; however, neither the specification, nor the claim, explicitly limits the invention to any specifically disclosed or recited embodiments. Consequently, the substituted carboxamides of the formula (I-a), formula (I-b), and/or formula (I-c) have been rendered indefinite by the use of the phrase, optionally substituted, with regard to R3, R4, R5, RA1, RA2, RA3, RA4, RA5, RB1, RB2, RB3, RB4, RB5, RC1, RC2, RC3, RC4, and/or RC5, respectively.
Moreover, the inventor or joint inventor should further note that [C]laims which depend from indefinite claims are also indefinite. {See Ex parte Cordova, 10 USPQ 2d 1949, 1952 (PTO Bd. App. 1989)}.
The examiner suggests amending the claims, particularly as stated in the section above entitled New Claim Objections, to overcome this rejection.
Claim 6 is further rejected under 35 U.S.C. § 112(b) as being indefinite for failing to set forth the subject matter which the inventor or joint inventor regards as the invention.
The inventor or joint inventor should note that claim 6 recites the limitation, The amide derivative according to claim 1, wherein… R3 is substituted or unsubstituted C1-4 alkyl, in lines 1-4 of the claim. There is insufficient antecedent basis, in claim 1, for this limitation, with regard to the substituted carboxamides of the formula (I-a), formula (I-b), and/or formula (I-c), respectively. According to claim 1, R3 is not recited as substituted or unsubstituted, with regard to the substituted carboxamides of the formula (I-a), formula (I-b), and/or formula (I-c), respectively.
The examiner suggests amending the claim, particularly as stated in the section above entitled New Claim Objections, to overcome this rejection.
Claim 7 is further rejected under 35 U.S.C. § 112(b) as being indefinite for failing to set forth the subject matter which the inventor or joint inventor regards as the invention.
The inventor or joint inventor should note that claim 7 recites the limitation, The amide derivative according to claim 1, wherein… RC1, RC2 is… substituted or unsubstituted C1-4 alkyl, in lines 1-10 of the claim. There is insufficient antecedent basis, in claim 1, for this limitation, with regard to the substituted carboxamides of the formula (I-a), formula (I-b), and/or formula (I-c), respectively. According to claim 1, neither RC1, nor RC2, is recited as substituted or unsubstituted, with regard to the substituted carboxamides of the formula (I-a), formula (I-b), and/or formula (I-c), respectively.
The examiner suggests amending the claim, particularly as stated in the section above entitled New Claim Objections, to overcome this rejection.
Claim 8 is further rejected under 35 U.S.C. § 112(b) as being indefinite for failing to set forth the subject matter which the inventor or joint inventor regards as the invention.
The inventor or joint inventor should note that claim 8 recites the limitation, The amide derivative according to claim 1, wherein… RC1 is… 2-aminoethyl, 2-hydroxyethyl, or 2-methoxy-ethyl, in lines 1-9 of the claim. There is insufficient antecedent basis, in claim 1, for this limitation, with regard to the substituted carboxamides of the formula (I-a), formula (I-b), and/or formula (I-c), respectively. According to claim 1, RC1 is not recited as 2-aminoethyl, 2-hydroxyethyl, or 2-methoxyethyl (i.e. substituted), with regard to the substituted carboxamides of the formula (I-a), formula (I-b), and/or formula (I-c), respectively.
The examiner suggests amending the claim, particularly as stated in the section above entitled New Claim Objections, to overcome this rejection.
Claims 9 and 19 are further rejected under 35 U.S.C. § 112(b) as being indefinite for failing to set forth the subject matter which the inventor or joint inventor regards as the invention.
The inventor or joint inventor should note that claim 9 recites the limitation, The amide derivative according to claim 1, wherein… (1) R3 is… 2-dimethylaminoethyl, 2-hydroxyethyl, or 2-methoxyethyl; (2) ArA is… difluoromethoxy or 4-difluoromethoxy-2-fluorphenyl; (3) ArB is… difluoromethoxy; and (4) HetarC is… hydroxyethylpyrazolyl, methoxyethylpyrazolyl, aminoethyl-triazolyl, hydroxyethltriazolyl, or methoxyethyltriazolyl. There is insufficient antecedent basis, in claim 1, for this limitation, with regard to the substituted carboxamides of the formula (I-a), formula (I-b), and/or formula (I-c), respectively. According to claim 1, (1) R3 is not recited as 2-dimethylaminoethyl, 2-hydroxyethyl, or 2-methoxyethyl; (2) ArA is not recited as difluoromethoxy or 4-difluoromethoxy-2-fluorphenyl; (3) ArB is not recited as difluoromethoxy; and (4) HetarC is not recited as hydroxyethylpyrazolyl, methoxyethylpyrazolyl, aminoethyltriazolyl, hydroxyethl-triazolyl, or methoxyethyltriazolyl, respectively, with regard to the substituted carboxamides of the formula (I-a), formula (I-b), and/or formula (I-c), respectively.
Moreover, the inventor or joint inventor should further note that [C]laims which depend from indefinite claims are also indefinite. {See Ex parte Cordova, 10 USPQ 2d 1949, 1952 (PTO Bd. App. 1989)}.
The examiner suggests amending the claims, particularly as stated in the section above entitled New Claim Objections, to overcome this rejection.
Claim 10 is further rejected under 35 U.S.C. § 112(b) as being indefinite for failing to set forth the subject matter which the inventor or joint inventor regards as the invention.
The inventor or joint inventor should note that claim 0 recites the limitation, A compound according to claim 1 selected from the group consisting of:…, in lines 1-2of the claim. There is insufficient antecedent basis, in claim 1, for this limitation, with regard to the following substituted carboxamides: 34, 41, 46, 50, 61, 65-68, 70-75, 78-81, 84-88, and 93-97, respectively. According to claim 1, the aforementioned substituted carboxamides are substituted carboxamides of the formula (I-a), formula (I-b), and/or formula (I-c), particularly with regard to R1, R2, R3, and/or R6, respectively.
The examiner suggests amending the claim, particularly as stated in the section above entitled New Claim Objections, to overcome this rejection.
Allowable Subject Matter
No claims are allowed.
Conclusion
The inventor’s or joint inventor’s arguments and/or the Amendments to the Claims, filed February 26, 2026, necessitated the new grounds of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). The inventor or joint inventor is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.
Any inquiry concerning this communication or earlier communications from the Examiner should be directed to DOUGLAS M. WILLIS, whose telephone number is 571-270-5757. The Examiner may normally be reached on Monday thru Thursday from 8:00-6:00 EST. The Examiner is also available on alternate Fridays.
If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, Mr. Jeffrey Murray, may be reached on 571-272-9023. The fax phone number for the organization where this invention or proceeding is assigned is 571-273-8300.
Information regarding the status of an invention may be obtained from Patent Center. For more information about Patent Center, see https://www.uspto.gov/patents/apply/patent-center. Should you have questions on access to Patent Center, contact the Patent Electronic Business Center (PEBC) at 866-217-9197 (toll-free) or ebc@uspto.gov.
/DOUGLAS M WILLIS/
Primary Examiner, Art Unit 1624